These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38641148)

  • 1. Early recovery of natural killer cells post T-cell depleted allogeneic stem cell transplantation using alemtuzumab "in the bag".
    Davison GM; Opie JJ; Davids SFG; Mohammed R; Novitzky N
    Transpl Immunol; 2024 Jun; 84():102045. PubMed ID: 38641148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Memory T-cell enriched haploidentical transplantation with NK cell addback results in promising long-term outcomes: a phase II trial.
    Naik S; Li Y; Talleur AC; Selukar S; Ashcraft E; Cheng C; Madden RM; Mamcarz E; Qudeimat A; Sharma A; Srinivasan A; Suliman AY; Epperly R; Obeng EA; Velasquez MP; Langfitt D; Schell S; Métais JY; Arnold PY; Hijano DR; Maron G; Merchant TE; Akel S; Leung W; Gottschalk S; Triplett BM
    J Hematol Oncol; 2024 Jun; 17(1):50. PubMed ID: 38937803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reconstitution of T and NK cells after haploidentical hematopoietic cell transplantation using αβ T cell-depleted grafts and the clinical implication of γδ T cells.
    Park M; Im HJ; Lee YJ; Park N; Jang S; Kwon SW; Park CJ; Choi ES; Koh KN; Seo JJ
    Clin Transplant; 2018 Jan; 32(1):. PubMed ID: 29090489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD56-enriched donor cell infusion after post-transplantation cyclophosphamide for haploidentical transplantation of advanced myeloid malignancies is associated with prompt reconstitution of mature natural killer cells and regulatory T cells with reduced incidence of acute graft versus host disease: A pilot study.
    Jaiswal SR; Zaman S; Nedunchezhian M; Chakrabarti A; Bhakuni P; Ahmed M; Sharma K; Rawat S; O'donnell P; Chakrabarti S
    Cytotherapy; 2017 Apr; 19(4):531-542. PubMed ID: 28131632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early Cytomegalovirus Reactivation and Expansion of CD56
    Jang JE; Hwang DY; Chung H; Kim SJ; Eom JI; Jeung HK; Song J; Kim JS; Cheong JW; Min YH
    Biol Blood Marrow Transplant; 2019 Oct; 25(10):2070-2078. PubMed ID: 31212079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of alemtuzumab-based T-cell depletion on graft compositional change in vitro and immune reconstitution early after allogeneic stem cell transplantation.
    Roex MCJ; Wijnands C; Veld SAJ; van Egmond E; Bogers L; Zwaginga JJ; Netelenbos T; von dem Borne PA; Veelken H; Halkes CJM; Falkenburg JHF; Jedema I
    Cytotherapy; 2021 Jan; 23(1):46-56. PubMed ID: 32948458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid immune reconstitution after a reduced-intensity conditioning regimen and a CD3-depleted haploidentical stem cell graft for paediatric refractory haematological malignancies.
    Chen X; Hale GA; Barfield R; Benaim E; Leung WH; Knowles J; Horwitz EM; Woodard P; Kasow K; Yusuf U; Behm FG; Hayden RT; Shurtleff SA; Turner V; Srivastava DK; Handgretinger R
    Br J Haematol; 2006 Nov; 135(4):524-32. PubMed ID: 17010105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of alemtuzumab pharmacokinetics on T-cell dynamics, graft-versus-host disease and viral reactivation in patients receiving allogeneic stem cell transplantation with an alemtuzumab-based T-cell-depleted graft.
    Loeff FC; van Egmond EHM; Moes DJAR; Wijnands C; Von Dem Borne PA; Veelken H; Falkenburg JHF; Jedema I; Halkes CJM
    Transpl Immunol; 2019 Dec; 57():101209. PubMed ID: 31207283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lowering the alemtuzumab dose in reduced intensity conditioning allogeneic hematopoietic cell transplantation is associated with a favorable early intense natural killer cell recovery.
    Gärtner F; Hieke S; Finke J; Bertz H
    Cytotherapy; 2013 Oct; 15(10):1237-44. PubMed ID: 23993297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.
    Lee DA; Denman CJ; Rondon G; Woodworth G; Chen J; Fisher T; Kaur I; Fernandez-Vina M; Cao K; Ciurea S; Shpall EJ; Champlin RE
    Biol Blood Marrow Transplant; 2016 Jul; 22(7):1290-1298. PubMed ID: 27090958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Haploidentical Stem Cell Transplantation in Children With Hematological Malignancies Using αβ
    Diaz MA; Zubicaray J; Molina B; Abad L; Castillo A; Sebastian E; Galvez E; Ruiz J; Vicario JL; Ramirez M; Sevilla J; González-Vicent M
    Front Immunol; 2019; 10():2504. PubMed ID: 31736949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Donor-derived natural killer cells infused after human leukocyte antigen-haploidentical hematopoietic cell transplantation: a dose-escalation study.
    Choi I; Yoon SR; Park SY; Kim H; Jung SJ; Jang YJ; Kang M; Yeom YI; Lee JL; Kim DY; Lee YS; Kang YA; Jeon M; Seol M; Lee JH; Lee JH; Kim HJ; Yun SC; Lee KH
    Biol Blood Marrow Transplant; 2014 May; 20(5):696-704. PubMed ID: 24525278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Joint Modeling of Immune Reconstitution Post Haploidentical Stem Cell Transplantation in Pediatric Patients With Acute Leukemia Comparing CD34
    Salzmann-Manrique E; Bremm M; Huenecke S; Stech M; Orth A; Eyrich M; Schulz A; Esser R; Klingebiel T; Bader P; Herrmann E; Koehl U
    Front Immunol; 2018; 9():1841. PubMed ID: 30154788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Favorable impact of natural killer cell reconstitution on chronic graft-versus-host disease and cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation.
    Kheav VD; Busson M; Scieux C; Peffault de Latour R; Maki G; Haas P; Mazeron MC; Carmagnat M; Masson E; Xhaard A; Robin M; Ribaud P; Dulphy N; Loiseau P; Charron D; Socié G; Toubert A; Moins-Teisserenc H
    Haematologica; 2014 Dec; 99(12):1860-7. PubMed ID: 25085354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of alemtuzumab in pediatric patients undergoing ex vivo T-cell-depleted haploidentical hematopoietic cell transplantation.
    Bhoopalan SV; Cross SJ; Panetta JC; Triplett BM
    Cancer Chemother Pharmacol; 2020 Dec; 86(6):711-717. PubMed ID: 33037919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced-intensity conditioning containing low-dose alemtuzumab before allogeneic peripheral blood stem cell transplantation: graft-versus-host disease is decreased but T-cell reconstitution is delayed.
    Dodero A; Carrabba M; Milani R; Rizzo E; Raganato A; Montefusco V; Farina L; Milanesi M; Longoni P; Carlo-Stella C; Corradini P
    Exp Hematol; 2005 Aug; 33(8):920-7. PubMed ID: 16038785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved Relapse-Free Survival in Patients With High Natural Killer Cell Doses in Grafts and During Early Immune Reconstitution After Allogeneic Stem Cell Transplantation.
    Minculescu L; Fischer-Nielsen A; Haastrup E; Ryder LP; Andersen NS; Schjoedt I; Friis LS; Kornblit BT; Petersen SL; Sengelov H; Marquart HV
    Front Immunol; 2020; 11():1068. PubMed ID: 32547559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune reconstitution at 6 months following T-cell depleted hematopoietic stem cell transplantation is predictive for treatment outcome.
    Novitzky N; Davison GM; Hale G; Waldmann H
    Transplantation; 2002 Dec; 74(11):1551-9. PubMed ID: 12490788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Granulocyte Colony-Stimulating Factor-Mobilized Allografts Contain Activated Immune Cell Subsets Associated with Risk of Acute and Chronic Graft-versus-Host Disease.
    Vasu S; Geyer S; Bingman A; Auletta JJ; Jaglowski S; Elder P; O'Donnell LC; Bradbury H; Kitzler R; Andritsos L; Blum W; Klisovic R; Penza S; Efebera Y; Hofmeister C; Benson DM; Muthusamy N; Lozanski G; Devine SM
    Biol Blood Marrow Transplant; 2016 Apr; 22(4):658-668. PubMed ID: 26743340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.